Pintarnya | $16,700,000 | (Aug 26, 2025)
Barti | $12,000,000 | (Aug 26, 2025)
Soil Action, Inc. | $5,250,000 | (Aug 26, 2025)
Certified by Founder
Lodge
Remedy Plan Therapeutics
start up
United States
- Gaithersburg, MD
- 14/05/2025
- Unknown
- $18,000,000
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedy’s groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. We are advancing a robust pipeline of tunable NAMPT inhibitors, to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders.
Remedy's lead asset is RPT1G. With a favorable efficacy and tolerability profile, RPT1G will be advancing to the clinic in 2024.
- Industry Biotechnology
- Website https://remedyplan.com/
- LinkedIn https://www.linkedin.com/company/remedy-plan/
Irys | $10,000,000 | (Aug 26, 2025)
Arintra | $21,000,000 | (Aug 26, 2025)
Oway | $4,000,000 | (Aug 26, 2025)
Paragraf | $55,000,000 | (Aug 26, 2025)
Genow | $1,921,342 | (Aug 26, 2025)
Luna Diabetes | $23,600,000 | (Aug 26, 2025)
Dirac, Inc. | $10,700,000 | (Aug 26, 2025)
STARK | $62,000,000 | (Aug 26, 2025)
Incyclix Bio | $11,250,000 | (Aug 26, 2025)